Development of a facile fluorescent assay for the detection of 80 mutations within the p53 gene

被引:17
作者
Hodgson, DR
Foy, CA
Partridge, M
Pateromichelakis, S
Gibson, NJ
机构
[1] AstraZeneca Diagnost, Northwich CW9 7RA, Cheshire, England
[2] Kings Coll Hosp London, Maxillofacial Unit Oncol, London, England
关键词
D O I
10.1007/BF03402148
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Alterations in the p53 tumor suppressor gene constitute one of the most frequent genetic events associated with the development of human cancers. Determination of an individual's p53 status may be of value in early diagnosis, prediction of response to treatment, and for the detection of minimal residual cancer. Recent studies have also revealed that specific mutations affecting the p53 gene are associated with a poor outcome. The majority of tumor biopsies that are sent for study in the laboratory contain neoplastic cells intermingled with stroma, such that the detection of alterations in the p53 gene requires a tumor enrichment technique and/or highly sensitive mutation detection technologies. Thus, it is desirable that a clinically useful assay for detecting point mutations in the p53 gene function in the presence of significant quantities of wild-type sequence and identify the critical sequence aberrations. Materials and Methods: We utilized molecular beacons in a real-time allele-specific PCR format to obtain reference data on samples of quantitatively known p53 mutation status. These data have been statistically analyzed and the results used to detect p53 mutations, indicating the presence of occult tumor. Results: We describe validation of a simple, rapid, sensitive, and quantitative ARMS assay for identifying the levels of 80 point mutations within the p53 gene that, when mutated, constitute at least 1% of the total p53 sequences. Conclusions: The assay successfully identifies rare p53 gene mutations in clinical samples and overcomes many of the limitations of current technologies.
引用
收藏
页码:227 / 237
页数:11
相关论文
共 50 条
[1]   Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients [J].
Aas, T ;
Borresen, AL ;
Geisler, S ;
SmithSorensen, B ;
Johnsen, H ;
Varhaug, JE ;
Akslen, LA ;
Lonning, PE .
NATURE MEDICINE, 1996, 2 (07) :811-814
[2]   Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array [J].
Ahrendt, SA ;
Halachmi, S ;
Chow, JT ;
Wu, L ;
Halachmi, N ;
Yang, SC ;
Wehage, S ;
Jen, J ;
Sidransky, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (13) :7382-7387
[3]   P53 overexpression in head and neck carcinoma and radiotherapy results [J].
Awwad, S ;
Jaros, E ;
Somes, J ;
Lunec, J .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 34 (02) :323-332
[4]  
Barbareschi M, 1996, APPL IMMUNOHISTOCHEM, V4, P106
[5]   Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer [J].
Berns, EMJJ ;
van Staveren, IL ;
Look, MP ;
Smid, M ;
Klijn, JGM ;
Foekens, JA .
BRITISH JOURNAL OF CANCER, 1998, 77 (07) :1130-1136
[6]  
Berns EMJJ, 2000, CANCER RES, V60, P2155
[7]  
BORRESENDALE AL, 1997, ESO SCI UPDATES, V1
[8]   OVEREXPRESSION OF P53 PREDICTS ORGAN PRESERVATION USING INDUCTION CHEMOTHERAPY AND RADIATION IN PATIENTS WITH ADVANCED LARYNGEAL-CANCER [J].
BRADFORD, CR ;
ZHU, SB ;
WOLF, GT ;
POORE, J ;
FISHER, SG ;
BEALS, T ;
MCCLATCHEY, KD ;
CAREY, TE ;
HONG, WK ;
URBA, S ;
ENDICOTT, JW ;
CLOSE, L ;
FISHER, SR ;
TOOHILL, RJ ;
KARP, D ;
MILLER, DM ;
CHEUNG, NK ;
WEAVER, A ;
HILLEL, AD ;
SPAULDING, M ;
CHANG, BK ;
DOUGHERTY, B ;
DECONTI, R ;
GAREWAL, H ;
FYE, C .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 1995, 113 (04) :408-412
[9]   MOLECULAR ASSESSMENT OF HISTOPATHOLOGICAL STAGING IN SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK [J].
BRENNAN, JA ;
MAO, L ;
HRUBAN, RH ;
BOYLE, JO ;
EBY, YJ ;
KOCH, WM ;
GOODMAN, SN ;
SIDRANSKY, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (07) :429-435
[10]  
Brown JM, 1999, CANCER RES, V59, P1391